Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens

Optimal Treatment?

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

Original languageEnglish (US)
Article number39
JournalCurrent Infectious Disease Reports
Volume17
Issue number8
DOIs
StatePublished - Aug 23 2015

Fingerprint

Ventilator-Associated Pneumonia
Anti-Bacterial Agents
Therapeutics
Bacteria
Survival

Keywords

  • Antibiotics
  • Outcomes
  • Ventilator-associated pneumonia

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

@article{f0d3902661564798a2fbc9a0fea2a957,
title = "Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?",
abstract = "Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.",
keywords = "Antibiotics, Outcomes, Ventilator-associated pneumonia",
author = "Bailey, {Kristina L} and Kalil, {Andre C}",
year = "2015",
month = "8",
day = "23",
doi = "10.1007/s11908-015-0494-5",
language = "English (US)",
volume = "17",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "8",

}

TY - JOUR

T1 - Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens

T2 - Optimal Treatment?

AU - Bailey, Kristina L

AU - Kalil, Andre C

PY - 2015/8/23

Y1 - 2015/8/23

N2 - Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

AB - Ventilator-associated pneumonia (VAP) due to multidrug-resistant bacteria (MDR) is an emerging problem worldwide. Both gram-negative and gram-positive microorganisms are associated with VAP. We first describe the magnitude of the problem of MDR VAP followed by its clinical impact on survival outcomes, with the primary aim to review the optimal antibiotic choices to treat patients with MDR VAP. We discuss the challenges of intravenous and inhaled antibiotic treatments, as well as of monotherapy and combination antimicrobial therapies.

KW - Antibiotics

KW - Outcomes

KW - Ventilator-associated pneumonia

UR - http://www.scopus.com/inward/record.url?scp=84935024029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935024029&partnerID=8YFLogxK

U2 - 10.1007/s11908-015-0494-5

DO - 10.1007/s11908-015-0494-5

M3 - Article

VL - 17

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 8

M1 - 39

ER -